Schrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of “Buy” from Analysts

Shares of Schrödinger, Inc. (NASDAQ:SDGR) have been given an average rating of “Buy” by the six analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $32.80.

A number of brokerages recently issued reports on SDGR. KeyCorp raised their price objective on Schrödinger from $30.00 to $32.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th. Piper Sandler lowered their target price on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Thursday, February 27th.

Insider Activity at Schrödinger

In related news, insider Karen Akinsanya sold 16,723 shares of the firm’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $25.09, for a total transaction of $419,580.07. Following the completion of the transaction, the insider now directly owns 15,625 shares in the company, valued at $392,031.25. This trade represents a 51.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SDGR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Schrödinger by 169.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,357,532 shares of the company’s stock worth $86,018,000 after buying an additional 2,737,728 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Schrödinger by 60.2% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,510,518 shares of the company’s stock worth $67,718,000 after acquiring an additional 1,319,464 shares during the period. Nikko Asset Management Americas Inc. raised its stake in shares of Schrödinger by 108.7% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 2,464,911 shares of the company’s stock valued at $47,499,000 after acquiring an additional 1,283,949 shares in the last quarter. American Century Companies Inc. purchased a new position in Schrödinger in the first quarter valued at $19,787,000. Finally, Stephens Investment Management Group LLC grew its stake in Schrödinger by 22.5% during the 1st quarter. Stephens Investment Management Group LLC now owns 1,969,941 shares of the company’s stock worth $38,887,000 after purchasing an additional 362,285 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Schrödinger Price Performance

Shares of SDGR stock opened at $25.47 on Tuesday. The company has a market capitalization of $1.87 billion, a PE ratio of -10.88 and a beta of 1.63. The firm’s 50-day moving average is $23.16 and its two-hundred day moving average is $22.35. Schrödinger has a 12 month low of $16.60 and a 12 month high of $28.47.

Schrödinger (NASDAQ:SDGR) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.01). The firm had revenue of $59.55 million for the quarter, compared to analysts’ expectations of $54.60 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The firm’s quarterly revenue was up 62.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.86) EPS. Sell-side analysts forecast that Schrödinger will post -2.37 EPS for the current year.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.